基蛋生物:新冠疫情下的战略取舍 Getein Biotech: Trade-Offs in Strategic Decision-Making under the Covid-19 Pandemic (Simplified Chinese version)

As of the end of 2019, the point-of-care testing (POCT) products of Getein Biotech Inc., an important in vitro diagnostics (IVD) enterprise, had been successfully applied to the detection of many diseases, including cardiovascular diseases, inflammation, kidney diseases, and blood coagulation disorders. Its market share and output value were both among the highest in the industry. In addition to improving its core POCT products, Getein Biotech firmly grasped industry opportunities to accelerate expansion in key IVD segments and build a complete product system. However, with the impact of COVID-19 in 2020, the enterprise, unlike its competitors in this industry, failed to seize the opportunity of developing COVID-19 test kits. As a result, its profits fell sharply, and its competitive position in the industry faced huge challenges. At the beginning of 2021, due to uncertainties about the COVID-19 pandemic, the enterprise was forced to integrate its original resources and capabilities and adjust its development strategy in order to establish sustainable competitive advantages.